A tale of two IPOs (plus one): Cabaletta prices well below range for $75M while Phathom bags $182M
When Cabaletta Bio and Phathom Pharmaceuticals penciled in $100 million IPOs alongside 4D Molecular Therapeutics back in the beginning of October, they appeared to be …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.